• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Twist Bioscience Spins Out DNA Data Storage as Independent Company

    5/5/25 7:10:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TWST alert in real time by email

    Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors

    Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors

    Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage

    Twist remains focused on serving customers across the life sciences spectrum and expanding revenue and gross margin while driving toward adjusted EBITDA breakeven, now expected by the end of fiscal 2026

    Twist to retain minority ownership in Atlas Data Storage

    Company to discuss news during earnings call and webcast today at 8:00am ET

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that the company has spun out its DNA data storage technology application as an independent company, named Atlas Data Storage ("Atlas").

    "There are many applications of synthetic DNA with the potential to have an incredible impact on the world. With this spin out, both Twist and Atlas are able to move with full force in growing those applications," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. "With this transaction and a pure-play DNA data storage focused business, Atlas receives the investment needed to accelerate technology development and drive toward early access customer engagement while Twist continues to share in the upside opportunity for DNA data storage. This transaction also allows Twist to focus on continued revenue growth and our objective of achieving adjusted EBITDA breakeven and profitability. With the launch of Atlas, we now expect to achieve adjusted EBITDA breakeven by the end of fiscal 2026."

    Under the terms of the contribution and license agreements, Twist assigned and licensed its DNA data storage technology to Atlas in exchange for Twist receiving a minority ownership interest upon close, an upfront cash payment and a secured promissory note. Twist retains an ownership stake in Atlas and may participate in the upside of DNA data storage through future technology and commercial milestone payments, and a revenue share through royalties on future sales of Atlas' products and services. In addition, Twist will benefit from technology advancements made by Atlas where it applies to Twist's product groups.

    "The data storage market has enormous potential as humans, corporations and organizations generate more and more data that needs to be preserved. By operating as an independent company, Atlas is able to focus solely on bringing DNA data storage from technology to commercialization and invest in all the functions needed to enter the commercial market," said Varun Mehta, CEO of Atlas Data Storage. "With technology licensed from Twist and an initial close, Atlas is well positioned to drive toward commercialization."

    Emily Leproust, CEO and co-founder of Twist will serve on the board of directors of Atlas. The companies will operate independently with separate management teams. George Kadifa, managing director of Sumeru Equity Partners, will serve as executive chairman of the Atlas board and Varun Mehta, will serve as CEO of Atlas. Mr. Mehta brings significant experience in the data storage industry and has led several successful startups, including Nimble Storage, which was acquired by Hewlett Packard. Twist co-founder and general manager of DNA data storage, Bill Banyai, Ph.D., will move to Atlas and serve as its CTO.

    An independent special committee of the Twist Board of Directors approved the process of the spin out and the terms of the agreement. Jefferies LLC served as financial advisor to the independent special committee and to Twist.

    Non-GAAP Information

    This release includes projections of adjusted EBITDA, which is a non-GAAP financial measure, for the period presented. Adjusted EBITDA is defined as net loss adjusted to exclude interest income, interest expense, income tax expense, depreciation and amortization, other income/expense, net, stock-based compensation expense, restructuring and other costs, impairment of long-lived assets, change in fair value of contingent considerations and holdbacks, and other items that we believe are not indicative of our ongoing results. This non-GAAP measure is not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. A reconciliation of adjusted EBITDA in fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because Twist does not provide guidance on GAAP net loss and is not able to present the various reconciling cash and non-cash items between GAAP net loss and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company's future hiring and retention needs, as well as the future fair market value of its common stock, all of which is difficult to predict and is subject to change. The actual amount of these expenses during fiscal 2026 will have a significant impact on Twist's future GAAP financial results.

    Conference Call Information

    The company plans to hold a conference call and live audio webcast for analysts and investors today at 8:00 a.m. Eastern Time to discuss this news and the company's fiscal second quarter 2025 financial results. The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

    About Atlas Data Storage, Inc.

    Atlas Data Storage is a technology company building end-to-end DNA data storage. For additional information, please visit www.AtlasDS.com.

    About Twist Bioscience Corporation

    At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

    Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.

    Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

    Twist Bioscience Legal Notice Regarding Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing and ability of Twist to achieve adjusted EBITDA breakeven, the expected benefits of the spin-out, expectations relating to future contingent payments, expectations with respect to and Atlas Data Storage's ability to accelerate the technology development and commercialization of DNA data storage, and expectations relating to Altas Data Storage's ability to close committed financing and close additional rounds of financing. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results or achievements to be materially different from any future results or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability of Atlas to further develop DNA data storage capabilities and commercialize products and related services, market acceptance of such products and services and competition by other data storage providers. For a description of certain risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K filed with the SEC on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250505213784/en/

    For Investors:

    Angela Bitting

    SVP, Corporate Affairs

    925-202-6211

    [email protected]

    For Media:

    Amanda Houlihan

    Communications Manager

    774-265-5334

    [email protected]

    Get the next $TWST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TWST

    DatePrice TargetRatingAnalyst
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    3/2/2022Outperform
    Cowen
    2/7/2022$130.00 → $75.00Overweight
    Barclays
    More analyst ratings

    $TWST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    3/26/21 3:51:09 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Twist Bioscience with a new price target

    Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00

    12/13/24 8:32:53 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Twist Bioscience with a new price target

    Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00

    6/4/24 7:44:10 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience upgraded by Goldman with a new price target

    Goldman upgraded Twist Bioscience from Neutral to Buy and set a new price target of $45.00 from $25.00 previously

    1/17/24 7:47:50 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    SEC Filings

    View All

    $TWST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $TWST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

    SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    8/12/25 6:11:54 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

    SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    8/7/25 3:19:02 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Twist Bioscience Corp (0001581280) (Filer)

    8/6/25 4:05:45 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. "We designed this panel to break the status quo in genomic profiling by offering laboratories a powerful alternative to locked, one-size-fits-all solutions," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "With our customizable c

    8/19/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios

    8/6/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter fiscal 2025 ended June 30, 2025. "A strong balance sheet and disciplined cost-management underpin our focused business execution," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal third quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call a

    8/4/25 7:15:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Blake Katryn claimed no ownership of stock in the company (SEC Form 3)

    3 - Twist Bioscience Corp (0001581280) (Issuer)

    8/7/25 4:05:11 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Blake Katryn was granted 14,353 shares (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    8/7/25 4:05:13 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP of Human Resources Green Paula sold $35,597 worth of shares (1,255 units at $28.36), decreasing direct ownership by 0.98% to 126,206 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    8/6/25 4:05:13 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Financials

    Live finance-specific insights

    View All

    Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter fiscal 2025 ended June 30, 2025. "A strong balance sheet and disciplined cost-management underpin our focused business execution," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal third quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call a

    8/4/25 7:15:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025

    Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, before the opening of the market on August 4, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Invest

    7/14/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its f

    5/5/25 7:15:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Leadership Updates

    Live Leadership Updates

    View All

    Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios

    8/6/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar

    10/15/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him

    1/5/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 2:38:08 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Twist Bioscience Corporation

    SC 13G - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 9:39:34 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/5/24 6:07:26 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care